Consequently, monitoring changes in PGC1α expression in patient samples during and after treatment can provide insights into tumor response and the progression towards chemoresistance, enabling timely adjustments to alternative treatment regimens before the disease advances. The gene discussed is PPARGC1A; the disease is neoplasm.